StockDrifts LogoStockDrifts

Daewon Pharmaceutical 003220

Company
대원제약Daewon Pharmaceutical
Insiders
2
Buys
5
Total Value
₩149M ($103K)
Avg Return
-5.07%
Last Filing
2026-06-08

Daewon Pharmaceutical (003220) has 5 disclosed insider purchases and 1 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩149M ($103K) in reported transaction value. The earliest filing StockDrifts holds for Daewon Pharmaceutical is dated 2024-01-01; the most recent is 2026-06-08. Across these filings the average return since disclosure is -5.07%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-06-08SELL증여
임한일
Lim Han-il
vice president-15.0K₩12,400+23.9%₩186M ($129K)
2026-03-12BUYMarket Buy
임한일
Lim Han-il
vice president1.1K---
2026-03-11BUYMarket Buy
임한일
Lim Han-il
vice president1.9K---
2025-02-18BUYMarket Buy
임한일
Lim Han-il
vice president2.0K₩14,510-17.7%₩29M ($20K)
2025-02-17BUYMarket Buy
임한일
Lim Han-il
vice president1.0K₩14,460-17.4%₩14M ($10K)
2025-01-01BUY신규선임
강종환
Jong-hwan Kang
moving708₩14,400-17.1%₩10M ($7K)
2024-09-05BUYMarket Buy
임한일
Lim Han-il
vice president3.2K₩14,200-15.9%₩46M ($32K)
2024-07-18SELLMarket Sell
강주인
Kang Joo-in
moving-3.4K₩17,250+30.8%₩59M ($41K)
2024-01-01BUY신규선임
오준일
Oh Jun-il
moving1.1K₩15,880-24.8%₩17M ($12K)

Frequently asked questions

Who has been buying Daewon Pharmaceutical stock?
2 distinct insiders have filed 5 disclosed insider purchases in Daewon Pharmaceutical (003220), most recently on 2026-06-08. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Daewon Pharmaceutical have?
Daewon Pharmaceutical has 5 buy-side and 1 sell-side disclosures on record, covering ₩149M ($103K) in total reported value, spanning 2024-01-01 to 2026-06-08.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.